Trial · NCT01948830
Adverse events296
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 296
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Age-related macular degeneration (Fellow eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 9 | 323 | |
| other | Age-related macular degeneration (Fellow eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 4 | 326 | |
| other | Blepharitis (Fellow eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 6 | 323 | |
| other | Blepharitis (Fellow eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 8 | 326 | |
| other | Blepharitis (Study eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 5 | 323 | |
| other | Blepharitis (Study eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 6 | 326 | |
| other | Cataract (Fellow eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 7 | 323 | |
| other | Cataract (Fellow eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 10 | 326 | |
| other | Cataract (Study eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 7 | 323 | |
| other | Cataract (Study eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 7 | 326 | |
| other | Choroidal neovascularisation (Fellow eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 6 | 323 | |
| other | Choroidal neovascularisation (Fellow eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 7 | 326 | |
| other | Conjunctival haemorrhage (Study eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 14 | 323 | |
| other | Conjunctival haemorrhage (Study eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 19 | 326 | |
| other | Detachment of retinal pigment epithelium (Study eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 0 | 323 | |
| other | Detachment of retinal pigment epithelium (Study eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 4 | 326 | |
| other | Dry eye (Fellow eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 7 | 323 | |
| other | Dry eye (Fellow eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 6 | 326 | |
| other | Dry eye (Study eye) | Eye disorders | Group I Ranibizumab 0.5 mg TER | 6 | 323 | |
| other | Dry eye (Study eye) | Eye disorders | Group II Ranibizumab 0.5 mg Monthly | 7 | 326 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01948830/events